Targets › CYP4V2
3 programs from 3 companies in 5 trials: 3 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Dec 2026.
A cytochrome P450 monooxygenase involved in fatty acid metabolism in the eye. Catalyzes the omega-hydroxylation of polyunsaturated fatty acids (PUFAs) docosahexaenoate (DHA) and its precursor eicosapentaenoate (EPA), and may contribute to the homeostasis of these retinal PUFAs. (UniProt, Q6ZWL3)
Open in Phaseline: the race on CYP4V2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Vitalgen BioPharma | VGR-R01 CYP4V2-coding gene delivered by AAV vector | CYP4V2 | Phase 3 | Bietti Crystalline Dystrophy | Dec 2026 |
| Chigenovo Co., Ltd | ZVS101e AAV8-delivered CYP4V2 gene therapy | CYP4V2 | Phase 3 | Bietti Crystalline Corneoretinal Dystrophy; Bietti's Crystalline Dystrophy | Dec 2028 |
| NGGT (Suzhou) Biotechnology | NGGT001 AAV-mediated CYP4V2 gene delivery via subretinal injection | CYP4V2 | Phase 1 | Bietti Crystalline Corneoretinal Dystrophy | Sep 2029 |
Bietti Crystalline Corneoretinal Dystrophy (2) Bietti Crystalline Dystrophy (2) Bietti's Crystalline Dystrophy (1)
other (1), protein or peptide (1), small molecule (1)
Chigenovo Co., Ltd (1) NGGT (Suzhou) Biotechnology (1) Shanghai Vitalgen BioPharma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.